Donanemab
7 Posts
The TRAILBLAZER-ALZ 2 study (NCT04437511) demonstrated significant clinical benefits of donanemab-azbt in early symptomatic Alzheimer disease (AD). Here are the key findings:Efficacy OutcomesCognitive & Functional....
To minimize adverse reactions when administering Donanemab-azbt (Kisunla), follow these evidence-based protocols:Pre-Infusion PreparationBaseline Assessments:Perform APOE ε4 genotyping (higher ARIA risk in homozygotes).Obtain a brain MRI....
The criteria for stopping Donanemab-azbt (Kisunla) therapy are primarily based on amyloid plaque reduction and safety monitoring, as outlined in clinical guidelines and prescribing information:Primary....
Donanemab-azbt (Kisunla) demonstrates distinct advantages and trade-offs compared to other Alzheimer's treatments, particularly monoclonal antibody therapies like lecanemab and aducanumab. Here's a structured comparison:Mechanism of....
Frequent Adverse ReactionsAmyloid-Related Imaging Abnormalities (ARIA)ARIA-Edema (ARIA-E): Temporary brain swelling (24% incidence), often asymptomatic but may cause headaches, dizziness, or confusion[2][3][4].ARIA-Hemosiderin Deposition (ARIA-H): Microhemorrhages (25%)....
